Interventional Care

We notice that you are visiting us from . This site only services US-based visitors. Would you like to visit the site that is appropriate for your location?
Our IMPACT Program supports our customers in improving clinical metrics, with a focus on reducing CLABSIs. Through this collaborative framework, we emphasize real world process improvements and outcomes in healthcare facilities employing best practices.
To demonstrate our confidence in Prevantics® Device Swab, we offer a money-back guarantee to program customers. Together, we can drive positive change in healthcare.
Our IMPACT Program supports our customers in improving clinical metrics, with a focus on reducing CLABSIs. Through this collaborative framework, we emphasize real world process improvements and outcomes in healthcare facilities employing best practices.
To demonstrate our confidence in Prevantics® Device Swab, we offer a money-back guarantee to program customers. Together, we can drive positive change in healthcare.
Follow the steps to learn how our IMPACT Program works.
The Use of 3.15% Chlorhexidine Gluconate/70% Alcohol Hub Disinfection to Prevent Central Line-Associated Blood Stream Infections in Dialysis Patients …
The Prevantics Device Swab Clinical Compendium provides a complete guide to efficacy data, clinical studies and safety information for the product.
This video provides an overview of the benefits of Prevantics® Device Swab and how it compares to alternative options for…
This course qualifies for 1 CE / 1 IPU and corresponds to the following Infection Prevention Unit (IPU) domain(s): Identification…
Prior to 2020, there had been a significant ongoing and sustained reduction in the rate of central line-associated...
Every Infection Preventionist should know what The Center for Disease Control and Prevention’s (CDC) bundle checklist is to...
Despite a 46% reduction in central line-associated bloodstream infections (CLABSIs) in US healthcare facilities from 2008-2013, an estimated...
1https://arpsp.cdc.gov/profile/nhsn/clabsi
2https://www.ahrq.gov/hai/pfp/haccost2017-results.html#:~:text=Central%20Line%2DAssociated%20Bloodstream%20Infections,-Based%20on%20seven&text=Individual%20studies%20produced%20a%20broad,%2418%2C000%20to%20more%20than%20%2490%2C000 (23,389 x $48,108 (AHRQ cost avg CLABSI) = $1.13B)